Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Humacyte, Inc. (HUMA : NSDQ)
 
 • Company Description   
Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

Number of Employees: 220

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.19 Daily Weekly Monthly
20 Day Moving Average: 2,722,754 shares
Shares Outstanding: 155.12 (millions)
Market Capitalization: $184.59 (millions)
Beta: 1.64
52 Week High: $9.97
52 Week Low: $1.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.20% -29.45%
12 Week -69.64% -67.20%
Year To Date -76.44% -75.12%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2525 EAST NORTH CAROLINA HIGHWAY 54
-
DURHAM,NC 27713
USA
ph: 919-313-9633
fax: -
investors@humacyte.com http://www.humacyte.com
 
 • General Corporate Information   
Officers
Laura E. Niklason - President and Chief Executive Officer
Dale A. Sander - Chief Financial Officer and Treasurer
Kathleen Sebelius - Director
John Bamforth - Director
Michael T. Constantino - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 44486Q103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 05/09/25
Share - Related Items
Shares Outstanding: 155.12
Most Recent Split Date: (:1)
Beta: 1.64
Market Capitalization: $184.59 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/09/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 33.33%
vs. Previous Quarter: 51.52%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/25 - -
12/31/24 - -
09/30/24 - -
ROA
03/31/25 - -
12/31/24 - -89.16
09/30/24 - -93.82
Current Ratio
03/31/25 - -
12/31/24 - 2.40
09/30/24 - 1.10
Quick Ratio
03/31/25 - -
12/31/24 - 2.40
09/30/24 - 1.10
Operating Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Net Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Pre-Tax Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Book Value
03/31/25 - -
12/31/24 - -0.41
09/30/24 - -0.53
Inventory Turnover
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Equity
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Capital
03/31/25 - -
12/31/24 - -
09/30/24 - -
 

Powered by Zacks Investment Research ©